Key Takeaways HIMS is set to report Q3 results with EPS estimated to be 9 cents and revenues of $583.7 million.HIMS' new hormonal health offerings and AI enhancements aim to expand reach and lift user engagement in Q3.HIMS continues to scale via women's health launches and global digital expansion, driving long-term growth.Hims & Hers Health, Inc. (HIMS) is scheduled to report third-quarter 2025 results on Nov. 3, after the closing bell.In the last reported quarter, the company’s earnings per share (EPS) of ...

周三，Hims&Hers Health(HIMS.US)股价走高，截至发稿，该股涨超7%，报51.39美元。消息面上，该 公司宣布，2026年将通过与睾酮疗法创新领军企业Marius Pharmaceuticals合作，在其平台上独家推出一 款口服睾酮药物KYZATREX。这款药物已经获得美国食品药品监督管理局批准，无需注射，使用更加 便捷。据临床数据，KYZATREX可使高达96%的男性恢复正常睾酮水平，同时将"游离睾酮"翻倍提升。 游离睾酮被认为与精力、驱动力和身体表现密切相关，而该药物在提升疗效的同时保持了较低的不良反 应率。 ...